NCT05522387 2026-02-27An Open-Label Extension of XPro1595 in Patients With Alzheimer's DiseaseInmune Bio, Inc.Phase 2 Terminated11 enrolled
NCT04543188 2025-10-23A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain InvolvementPfizerPhase 1 Terminated65 enrolled 52 charts
NCT05321498 2023-09-28Study to Assess the Efficacy of XPro1595 in Patients With Mild Cognitive Impairment With Biomarkers of InflammationInmune Bio, Inc.Phase 2 Withdrawn
NCT01290692 2023-07-03Study To Test the Safety and Efficacy of TVI-Brain-1 As A Treatment for Recurrent Grade IV GliomaTVAX BiomedicalPhase 2 Completed14 enrolled 11 charts
NCT01081223 2023-06-01Phase I/II Study To Test The Safety and Efficacy of TVI-Brain-1 As A Treatment For Recurrent Grade IV GliomaTVAX BiomedicalPhase 1/2 Completed12 enrolled 11 charts
NCT00649207 2017-11-21A Phase I Study of ABT-888 in Combination With Conventional Whole Brain Radiation Therapy (WBRT) in Cancer Patients With Brain MetastasesAbbViePhase 1 Completed80 enrolled
NCT01386580 2015-01-22An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.BBB-Therapeutics B.V.Phase 1/2 Completed84 enrolled
NCT00643890 2012-02-22Study of AAV-GAD Gene Transfer Into the Subthalamic Nucleus for Parkinson's DiseaseNeurologix, Inc.Phase 2 Terminated44 enrolled
NCT00906516 2009-05-21Neuradiab® Combined With Bevacizumab (Avastin) Therapy in Patients With Recurrent Glioblastoma MultiformeBradmer Pharmaceuticals Inc.Phase 2 Unknown60 enrolled